东方证券研报指出，鱼跃医疗家用医疗器械龙头，布局广阔。公司核心业务涵盖四大领域：呼吸制氧、血糖及POCT、家用健康检测（电子血压计等）、临床器械及康复。公司新品布局围绕全球化、数字化和可穿戴化进行，同时，公司积极研发AI智能穿戴医疗设备，基于公司在医疗领域的技术积累，将建设“监测-预警-干预”全链条管线。2025年初，公司与Inogen签署《战略合作协议》。Inogen为一家美国呼吸制氧业务企业，拥有广泛的欧美销售渠道，预计将与公司优势互补，实现协作共赢。公司业务现已逐步回归疫情后的常态化、可持续发展轨道，作为国内家用医疗器械龙头，公司内生外延并举，产品线不断丰富，渠道持续开拓，长期空间广阔。根据可比公司2025年平均估值，给予公司2025年24倍PE，对应目标价48.24元，首次给予“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.